Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 20Phase 3 8Phase 1/2 7Phase 2/3 3Phase 4 2Phase NA 1

Status

Completed 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 8Liver Neoplasms 3Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Leukemia, Monocytic, Acute 1

Interventions

Sorafenib 3lenvatinib 2sintilimab 1pembrolizumab 1halofantrine 1glucose-regulated proteins 1camrelizumab 1Tranexamic Acid 1Thalidomide 1Sunitinib 1Standard of Care 1Saline Solution 1Oxaliplatin 1Nadroparin 1Lidocaine 1Injections 1Immune Checkpoint Inhibitors 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Folfox protocol 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Liver Neoplasms × Sorafenib × Clear all
NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01932385 2018-02-14

Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Qingdao Central Hospital

Phase 2/3 Completed
86 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01901692 2017-09-18

START

Asan Medical Center

Phase 2/3 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡